Pegylated liposomal doxorubicin in ovarian cancer

Robert Strother, Daniela Matei

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The encapsulation of doxorubicin in a pegylated liposomal matrix led to a reformulated agent with a different toxicity profile and improved clinical utility. Liposomal doxorubicin is devoid of the cardiac toxicity associated with doxorubicin, but is associated with predictable muco-cutaneous toxicity. The liposomal formulation leads to improved delivery to the target tumor tissue, allowing enhanced uptake by cancer cells. These properties translate into clinical utility in recurrent ovarian cancer as demonstrated by phase II and III trials, this proven clinical efficacy leading to FDA approval in second-line therapy for ovarian cancer. New combinations with cytotoxics, in particular with carboplatin, have demonstrated an acceptable toxicity profile and clinical utility in platinum-sensitive ovarian cancer. A favorable toxicity profile renders liposomal doxorubicin an ideal partner for combination regimens with other cytotoxics, and more recently with biological agents. Such combinations are the subject of ongoing clinical trials.

Original languageEnglish
Pages (from-to)639-650
Number of pages12
JournalTherapeutics and Clinical Risk Management
Volume5
Issue number1
StatePublished - 2009

Fingerprint

Ovarian Neoplasms
Toxicity
cancer
Doxorubicin
Carboplatin
Biological Factors
Platinum
Neoplasms
Clinical Trials
Skin
Encapsulation
Tumors
Cells
liposomal doxorubicin
Tissue
Therapeutics
Cardiotoxicity

Keywords

  • Doxorubicin
  • Liposomes
  • Ovarian cancer
  • Pegylated liposomal doxorubicin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Safety Research
  • Chemical Health and Safety

Cite this

Pegylated liposomal doxorubicin in ovarian cancer. / Strother, Robert; Matei, Daniela.

In: Therapeutics and Clinical Risk Management, Vol. 5, No. 1, 2009, p. 639-650.

Research output: Contribution to journalArticle

@article{2b312f68d4184d658ed121eeaf785bb5,
title = "Pegylated liposomal doxorubicin in ovarian cancer",
abstract = "The encapsulation of doxorubicin in a pegylated liposomal matrix led to a reformulated agent with a different toxicity profile and improved clinical utility. Liposomal doxorubicin is devoid of the cardiac toxicity associated with doxorubicin, but is associated with predictable muco-cutaneous toxicity. The liposomal formulation leads to improved delivery to the target tumor tissue, allowing enhanced uptake by cancer cells. These properties translate into clinical utility in recurrent ovarian cancer as demonstrated by phase II and III trials, this proven clinical efficacy leading to FDA approval in second-line therapy for ovarian cancer. New combinations with cytotoxics, in particular with carboplatin, have demonstrated an acceptable toxicity profile and clinical utility in platinum-sensitive ovarian cancer. A favorable toxicity profile renders liposomal doxorubicin an ideal partner for combination regimens with other cytotoxics, and more recently with biological agents. Such combinations are the subject of ongoing clinical trials.",
keywords = "Doxorubicin, Liposomes, Ovarian cancer, Pegylated liposomal doxorubicin",
author = "Robert Strother and Daniela Matei",
year = "2009",
language = "English",
volume = "5",
pages = "639--650",
journal = "Therapeutics and Clinical Risk Management",
issn = "1176-6336",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Pegylated liposomal doxorubicin in ovarian cancer

AU - Strother, Robert

AU - Matei, Daniela

PY - 2009

Y1 - 2009

N2 - The encapsulation of doxorubicin in a pegylated liposomal matrix led to a reformulated agent with a different toxicity profile and improved clinical utility. Liposomal doxorubicin is devoid of the cardiac toxicity associated with doxorubicin, but is associated with predictable muco-cutaneous toxicity. The liposomal formulation leads to improved delivery to the target tumor tissue, allowing enhanced uptake by cancer cells. These properties translate into clinical utility in recurrent ovarian cancer as demonstrated by phase II and III trials, this proven clinical efficacy leading to FDA approval in second-line therapy for ovarian cancer. New combinations with cytotoxics, in particular with carboplatin, have demonstrated an acceptable toxicity profile and clinical utility in platinum-sensitive ovarian cancer. A favorable toxicity profile renders liposomal doxorubicin an ideal partner for combination regimens with other cytotoxics, and more recently with biological agents. Such combinations are the subject of ongoing clinical trials.

AB - The encapsulation of doxorubicin in a pegylated liposomal matrix led to a reformulated agent with a different toxicity profile and improved clinical utility. Liposomal doxorubicin is devoid of the cardiac toxicity associated with doxorubicin, but is associated with predictable muco-cutaneous toxicity. The liposomal formulation leads to improved delivery to the target tumor tissue, allowing enhanced uptake by cancer cells. These properties translate into clinical utility in recurrent ovarian cancer as demonstrated by phase II and III trials, this proven clinical efficacy leading to FDA approval in second-line therapy for ovarian cancer. New combinations with cytotoxics, in particular with carboplatin, have demonstrated an acceptable toxicity profile and clinical utility in platinum-sensitive ovarian cancer. A favorable toxicity profile renders liposomal doxorubicin an ideal partner for combination regimens with other cytotoxics, and more recently with biological agents. Such combinations are the subject of ongoing clinical trials.

KW - Doxorubicin

KW - Liposomes

KW - Ovarian cancer

KW - Pegylated liposomal doxorubicin

UR - http://www.scopus.com/inward/record.url?scp=73649114809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73649114809&partnerID=8YFLogxK

M3 - Article

C2 - 19707541

AN - SCOPUS:73649114809

VL - 5

SP - 639

EP - 650

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

SN - 1176-6336

IS - 1

ER -